185991-07-5

AMD 3465 is a CXCR4 antagonist and in combination with monoclonal antibody, was shown to be potentially effective in reducing tumor growth and increasing survival in patient with B cell lymphoma

AMD3465 is also termed as{N-[1,4,8,11-tetraazacyclotetradecanyl-1,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine}. It controls oncogenic signaling and invasiveness in vitro. It inhibits breast cancer growth and metastasis in vivo. As a chemokine receptor 4 (CXCR4) antagonist, AMD3465 is ten times more efficient than bicyclam AMD3100.

Store at -20°C